• Robert M Reed, Howard J Cabral, Mark T Dransfield, Michael Eberlein, Christian A Merlo, Matthew J Mulligan, Giora Netzer, Pablo G Sanchez, Steven M Scharf, Don D Sin, and Bartholome R Celli.
• University of Maryland School of Medicine, Baltimore, MD. Electronic address: rreed@som.umaryland.edu.
• Chest. 2018 Mar 1; 153 (3): 697-701.

BackgroundThe BMI, obstruction, dyspnea, and exercise capacity (BODE) score is used to inform prognostic considerations for lung transplantation for COPD, but it has not been validated in this context. A large proportion of mortality in COPD is attributable to comorbidities that could preclude transplant candidacy. We hypothesized that patients with COPD who are selected as transplant candidates experience better survival than traditional interpretation of BODE scores might indicate.MethodsWe performed a retrospective analysis of survival according to the BODE score for patients with COPD in the United Network of Organ Sharing (UNOS) database of lung transplantation candidates (n = 4,377) compared with the cohort of patients with COPD in which the BODE score was validated (n = 625).ResultsMedian survival in the fourth quartile of BODE score was 59 months (95% CI, 51-77 months) in the UNOS cohort and 37 months (95% CI, 29-42 months) in the BODE validation cohort. In models controlling for BODE score and incorporating lung transplantation as a competing end point, the risk of death was higher in the BODE validation cohort (subhazard ratio, 4.8; 95% CI, 4.0-5.7; P < .001). The risk difference was greatest in the fourth quartile of BODE scores (SHR, 6.1; 95% CI, 4.9-7.6; P < .001).ConclusionsExtrapolation of prognosis based on the BODE score overestimates mortality risk in lung transplantation candidates with COPD. This is likely due to a lower prevalence of comorbid conditions attributable to the lung transplantation evaluation screening process.Published by Elsevier Inc.

28 keywords...

hide…